Featured Archives - Page 22 of 29 - Boston Life Sciences Times

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

December 17, 2025

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

December 16, 2025

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

THIS WEEK'S STORIES

Nimbus Therapeutics Completes Dose Escalation in Phase 1/2 Trial of WRN Inhibitor for MSI-H Tumors

December 19, 2025

Calluna Pharma Appoints Gijs van den Brink, MD, PhD, as Independent Director

December 16, 2025

NeoGenomics Says Natera Withdraws Appeal in RaDaR Patent Litigation

December 15, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Featured

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

Most Read

Manifold Raises $18 Million Series B to Expand Vertical AI Platform for Life Sciences

PureTech Appoints Robert Lyne as Chief Executive Officer

Orum Therapeutics Raises Approximately $100 Million to Advance Degrader Antibody Conjugate Programs

Syremis Therapeutics Launches With $165 Million Series A to Advance New Treatments for Mental Health Disorders

EDITOR PICKS

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

THIS WEEK'S STORIES

Nimbus Therapeutics Completes Dose Escalation in Phase 1/2 Trial of WRN Inhibitor for MSI-H Tumors

Calluna Pharma Appoints Gijs van den Brink, MD, PhD, as Independent Director

NeoGenomics Says Natera Withdraws Appeal in RaDaR Patent Litigation

POPULAR CATEGORY

ABOUT US

FOLLOW US